SpyGlass Pharma, Inc. (NASDAQ:SGP) — Market Cap & Net Worth
Market Cap & Net Worth: SpyGlass Pharma, Inc. (SGP)
SpyGlass Pharma, Inc. (NASDAQ:SGP) has a market capitalization of $696.61 Million ($696.61 Million) as of May 27, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10976 globally and #2740 in its home market, demonstrating a -14.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SpyGlass Pharma, Inc.'s stock price $20.84 by its total outstanding shares 33426557 (33.43 Million). Analyse SpyGlass Pharma, Inc. cash conversion from operations to see how efficiently the company converts income to cash.
SpyGlass Pharma, Inc. Market Cap History: 2026 to 2026
SpyGlass Pharma, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $696.61 Million to $696.61 Million (0.00% CAGR).
SpyGlass Pharma, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SpyGlass Pharma, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SGP by Market Capitalization
Companies near SpyGlass Pharma, Inc. in the global market cap rankings as of May 27, 2026.
Key companies related to SpyGlass Pharma, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.28 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #417 globally with a market cap of $65.82 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #583 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #605 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.28 Billion | $434.52 |
| #417 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $65.82 Billion | $638.88 |
| #583 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #605 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
SpyGlass Pharma, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, SpyGlass Pharma, Inc.'s market cap moved from $696.61 Million to $ 696.61 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $696.61 Million | -- |
End of Day Market Cap According to Different Sources
On May 26th, 2026 the market cap of SpyGlass Pharma, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $696.61 Million USD |
| MoneyControl | $696.61 Million USD |
| MarketWatch | $696.61 Million USD |
| marketcap.company | $696.61 Million USD |
| Reuters | $696.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intra… Read more